Ainos pioneers AI-powered digital nose technology with VOC detection breakthroughs for early disease diagnosis, industrial safety, and human-like sensory capabilities in robots

VELDONA^® low-dose oral interferon technology demonstrates huge potential in in viral, autoimmune, and veterinary treatments

Ainos Plans To Conduct the Study at National Taiwan University Hospital, a Premier Taiwanese Medical Center for HIV Management

The U.S. FDA Have Granted Orphan Drug Designation (ODD) for the Company's VELDONA^® Low-Dose Oral Interferon Formulation as a Potential Treatment for Oral Warts in HIV-Positive Patients